AR120040A1 - Compuesto heterocíclico - Google Patents
Compuesto heterocíclicoInfo
- Publication number
- AR120040A1 AR120040A1 ARP200102652A ARP200102652A AR120040A1 AR 120040 A1 AR120040 A1 AR 120040A1 AR P200102652 A ARP200102652 A AR P200102652A AR P200102652 A ARP200102652 A AR P200102652A AR 120040 A1 AR120040 A1 AR 120040A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- group optionally
- halogen atoms
- substituents selected
- membered monocyclic
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000002950 monocyclic group Chemical group 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 102100022537 Histone deacetylase 6 Human genes 0.000 abstract 1
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 abstract 1
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 abstract 1
- -1 atom halogen Chemical class 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019177815 | 2019-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR120040A1 true AR120040A1 (es) | 2022-01-26 |
Family
ID=73040188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102652A AR120040A1 (es) | 2019-09-27 | 2020-09-24 | Compuesto heterocíclico |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11453661B2 (enExample) |
| EP (1) | EP4034536A1 (enExample) |
| JP (1) | JP7602546B2 (enExample) |
| KR (1) | KR20220070465A (enExample) |
| CN (1) | CN114846012B (enExample) |
| AR (1) | AR120040A1 (enExample) |
| AU (1) | AU2020353984B2 (enExample) |
| BR (1) | BR112022005595A2 (enExample) |
| CA (1) | CA3156060A1 (enExample) |
| CL (1) | CL2022000763A1 (enExample) |
| CO (1) | CO2022005059A2 (enExample) |
| EC (1) | ECSP22026524A (enExample) |
| IL (1) | IL291413B2 (enExample) |
| MX (1) | MX2022003490A (enExample) |
| PE (1) | PE20220711A1 (enExample) |
| PH (1) | PH12022550748A1 (enExample) |
| TW (1) | TWI882012B (enExample) |
| WO (1) | WO2021060567A1 (enExample) |
| ZA (1) | ZA202204666B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| WO2021021979A2 (en) | 2019-07-30 | 2021-02-04 | Eikonizo Therapapeutics, Inc. | Hdac6 inhibitors and uses thereof |
| AU2020353984B2 (en) * | 2019-09-27 | 2025-09-25 | Takeda Pharmaceutical Company Limited | 2-isoindol-1,3,4-oxadiazole derivatives useful as HDAC6 inhibitors |
| CN114980887A (zh) | 2019-12-20 | 2022-08-30 | 特纳亚治疗股份有限公司 | 氟代烷基-噁二唑及其用途 |
| IL307883A (en) | 2021-04-23 | 2023-12-01 | Tenaya Therapeutics Inc | HDAC6 inhibitors for use in the treatment of dilated myocardial disease |
| WO2022235842A1 (en) | 2021-05-04 | 2022-11-10 | Tenaya Therapeutics, Inc. | 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef |
| CN114166824B (zh) * | 2021-12-08 | 2024-01-23 | 桂林医学院 | 一种辅剂示踪分析保健品中药物含量的方法 |
| EP4504190A4 (en) | 2022-04-08 | 2026-03-25 | Eikonizo Therapeutics Inc | OXADIAZOLE HDAC6 INHIBITORS AND THEIR USES |
| TW202400147A (zh) * | 2022-04-15 | 2024-01-01 | 大陸商勤浩醫藥(蘇州)有限公司 | 噁二唑化合物、包含其的藥物組合物及其用途 |
| AU2024240637A1 (en) * | 2023-03-21 | 2025-09-18 | Vivozon,Inc. | Double regulator for mglur5 and hdac6 and use thereof |
| WO2025067416A1 (zh) * | 2023-09-28 | 2025-04-03 | 勤浩医药（苏州）有限公司 | 一种hdac6抑制剂的结晶形式及其制备方法 |
| WO2025215092A1 (en) | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
| CN119823019A (zh) * | 2025-01-06 | 2025-04-15 | 沈阳药科大学 | 一种具有治疗特发性肺纤维化作用的吲哚类化合物及其制备方法和应用 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
| US20050227915A1 (en) | 2001-05-02 | 2005-10-13 | Steffan Joan S | Methods and reagents for treating neurodegenerative diseases and motor deficit disorders |
| ES2310213T3 (es) | 2001-05-02 | 2009-01-01 | The Regents Of The University Of California | Procedimiento para tratar trastornos neurodegenerativos, psiquiatricos y otros trastornos con inhibidores de desacetilasa. |
| US20040142859A1 (en) | 2002-05-02 | 2004-07-22 | Steffan Joan S. | Method for treating neurodegenerative, psychiatric, and other disorders with deacetylase inhibitors |
| WO2003032921A2 (en) | 2001-10-16 | 2003-04-24 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain |
| NZ550185A (en) | 2002-03-04 | 2008-10-31 | Merck Hdac Res Llc | Methods of inducing terminal differentiation Methods of inducing terminal differentiation |
| WO2003080864A1 (fr) | 2002-03-26 | 2003-10-02 | Exhonit Therapeutics Sa | Histone deacetylase: nouvelle cible moleculaire de la neurotoxicite |
| AU2003226014A1 (en) | 2002-03-28 | 2003-10-13 | Brigham And Women's Hospital, Inc. | Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease |
| ITMI20040876A1 (it) | 2004-04-30 | 2004-07-30 | Univ Degli Studi Milano | Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari |
| US20060018921A1 (en) | 2004-07-16 | 2006-01-26 | Baylor College Of Medicine | Histone deacetylase inhibitors and cognitive applications |
| GT200500321A (es) | 2004-11-09 | 2006-09-04 | Compuestos y composiciones como inhibidores de proteina kinase. | |
| CN101056632B (zh) * | 2004-11-09 | 2011-12-07 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
| US20060135612A1 (en) | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
| US8999289B2 (en) | 2005-03-22 | 2015-04-07 | President And Fellows Of Harvard College | Treatment of protein degradation disorders |
| CA2616537A1 (en) | 2005-07-27 | 2007-02-01 | University Of Florida Research Foundation, Inc. | Small compounds that correct protein misfolding and uses thereof |
| US20070078083A1 (en) | 2005-09-07 | 2007-04-05 | Braincells, Inc. | MODULATION OF NEUORGENESIS BY HDac INHIBITION |
| WO2007049262A1 (en) | 2005-10-27 | 2007-05-03 | Berand Limited | Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders |
| US8026260B2 (en) | 2005-11-03 | 2011-09-27 | Merck Sharp & Dohme Corp. | Histone deacetylase inhibitors with aryl-pyrazolyl-motifs |
| US20070207950A1 (en) | 2005-12-21 | 2007-09-06 | Duke University | Methods and compositions for regulating HDAC6 activity |
| GB0612273D0 (en) | 2006-06-21 | 2006-08-02 | Friedrich Miescher Inst For Bi | Prevention of muscle atrophy |
| US8088951B2 (en) | 2006-11-30 | 2012-01-03 | Massachusetts Institute Of Technology | Epigenetic mechanisms re-establish access to long-term memory after neuronal loss |
| WO2008073733A1 (en) | 2006-12-08 | 2008-06-19 | Kalypsys, Inc. | Salts of inhibitors of histone deacetylase for the treatment of disease |
| MX2009006327A (es) | 2006-12-15 | 2009-06-23 | Novartis Ag | Compuestos heterociclicos y metodos de uso de los mismos. |
| WO2008126932A2 (en) | 2007-04-09 | 2008-10-23 | Riken | Epigenetical regulation of brain plasticity |
| AU2008269154B2 (en) | 2007-06-27 | 2014-06-12 | Merck Sharp & Dohme Llc | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| WO2009027349A2 (en) | 2007-08-24 | 2009-03-05 | Oryzon Genomics Sa | Treatment and prevention of neurodegenerative diseases |
| US20090136461A1 (en) | 2007-11-28 | 2009-05-28 | Moon Suk Kim | Neuronal differentiation method of adult stem cells using small molecules |
| AU2013203735A1 (en) * | 2007-12-04 | 2013-05-02 | F. Hoffmann-La Roche Ag | Isoxazolo-pyridine derivatives |
| RU2012131164A (ru) | 2009-12-22 | 2014-01-27 | Селджин Корпорейшн | (метилсульфонил)этил-бензол-изоиндолиновые производные и их терапевтическое применение |
| WO2011088192A1 (en) | 2010-01-13 | 2011-07-21 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| KR101781663B1 (ko) | 2010-01-13 | 2017-09-25 | 템페로 파마슈티칼즈, 인크. | 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법 |
| WO2012018499A2 (en) | 2010-08-05 | 2012-02-09 | Acetylon Pharmaceuticals | Specific regulation of cytokine levels by hdac6 inhibitors |
| ES2647368T3 (es) | 2010-10-08 | 2017-12-21 | Vib Vzw | Inhibidores de HDAC para tratar la enfermedad de Charcot-Marie-Tooth |
| US20130203735A1 (en) | 2010-10-28 | 2013-08-08 | John T. Sisko | Caprolactam mglur5 receptor modulators |
| US8957066B2 (en) * | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| JP6250403B2 (ja) | 2011-02-28 | 2017-12-20 | バイオマリン ファーマシューティカル インク | ヒストン脱アセチル化酵素阻害剤 |
| EP2701699B1 (en) | 2011-04-28 | 2019-10-16 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| US20140235649A1 (en) | 2011-05-24 | 2014-08-21 | Lixte Biotechnology, Inc. | Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function |
| WO2013006408A1 (en) | 2011-07-01 | 2013-01-10 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| CN103764635B (zh) | 2011-07-08 | 2016-01-20 | 诺华股份有限公司 | 新的三氟甲基-噁二唑衍生物及其在疾病治疗中的用途 |
| WO2013009827A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013009810A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013009830A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| JP6169076B2 (ja) | 2011-07-20 | 2017-07-26 | ザ ジェネラル ホスピタル コーポレイション | 骨疾患の処置のためのヒストン脱アセチル化酵素６選択的阻害剤 |
| WO2013066839A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066833A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
| WO2013066838A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066831A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066835A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| EP2785713B1 (en) | 2011-11-28 | 2016-09-07 | Novartis AG | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| US9480673B2 (en) | 2012-03-29 | 2016-11-01 | The Regents Of The University Of Colorado, A Body Corporate | Composition and method for treating neurodegenerative disease |
| EP2841067A4 (en) | 2012-04-25 | 2016-04-13 | Univ California | MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME |
| WO2014006114A1 (en) | 2012-07-05 | 2014-01-09 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
| CN104894060B (zh) | 2014-03-03 | 2018-11-06 | 中国科学院上海生命科学研究院 | 诱导体细胞转分化为神经干细胞的方法及其应用 |
| MX2016011833A (es) | 2014-03-12 | 2017-03-29 | Chong Kun Dang Pharmaceutical Corp | Nuevos compuestos como inhibidores de histona desacetilasa 6 y composiciones farmaceuticas que los comprenden. |
| WO2016031815A1 (ja) | 2014-08-26 | 2016-03-03 | 武田薬品工業株式会社 | 複素環化合物 |
| JPWO2016039398A1 (ja) | 2014-09-09 | 2017-06-15 | 国立大学法人大阪大学 | 含窒素複素環誘導体、神経保護剤及び癌治療用医薬組成物 |
| WO2016126721A1 (en) | 2015-02-02 | 2016-08-11 | Forma Therapeutics, Inc. | 3-aryl-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors |
| CN107848695A (zh) * | 2015-06-30 | 2018-03-27 | Wm.雷格利 Jr.公司 | 用于糖果产品的包装和用于形成该包装的方法 |
| EP3327019A4 (en) | 2015-07-17 | 2019-04-03 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC CONNECTION |
| CN108026088B (zh) * | 2015-07-17 | 2021-02-12 | 武田药品工业株式会社 | 用作hdac抑制剂的噁二唑衍生物 |
| RU2695227C9 (ru) * | 2015-07-27 | 2020-03-04 | Чонг Кун Данг Фармасьютикал Корп. | Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция |
| NZ739211A (en) | 2015-07-27 | 2019-05-31 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same |
| PL3328843T3 (pl) | 2015-07-27 | 2023-02-27 | Chong Kun Dang Pharmaceutical Corp. | Związki będące pochodnymi 1,3,4 oksadiazolosulfonamidów jako inhibitor deacetylazy histonowej 6, oraz kompozycja farmaceutyczna je zawierająca |
| PT3331864T (pt) | 2015-08-04 | 2022-01-18 | Chong Kun Dang Pharmaceutical Corp | Compostos derivados de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica compreendendo os mesmos |
| US10406146B2 (en) | 2015-08-25 | 2019-09-10 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| CA3001666C (en) * | 2015-10-12 | 2021-03-30 | Chong Kun Dang Pharmaceutical Corp. | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| WO2017222952A1 (en) * | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
| US20180016314A1 (en) | 2016-07-12 | 2018-01-18 | Children's Hospital Medical Center | Treatment of disease via transcription factor modulation |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| JP2020520947A (ja) | 2017-05-24 | 2020-07-16 | オーファザイム エー／エス | 熱ショックタンパク質誘導因子および前頭側頭障害 |
| EP3661931A1 (en) * | 2017-07-31 | 2020-06-10 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US11458122B2 (en) | 2017-08-09 | 2022-10-04 | Children's Hospital Medical Center | Methods for treating diseases and nerve injuries |
| WO2019030692A1 (en) | 2017-08-10 | 2019-02-14 | Friedrich Miescher Institute For Biomedical Research | HDAC6 AND AGGREGATION OF PROTEINS |
| JP6910984B2 (ja) | 2018-03-30 | 2021-07-28 | 株式会社ホンダアクセス | 脱出ハンマー収容具 |
| KR102316234B1 (ko) * | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| HRP20250048T1 (hr) | 2018-10-22 | 2025-03-28 | Alumis Inc. | Inhibitori tyk2 i njihova uporaba |
| JP7470058B2 (ja) | 2019-01-30 | 2024-04-17 | 武田薬品工業株式会社 | 複素環化合物 |
| AU2020353984B2 (en) * | 2019-09-27 | 2025-09-25 | Takeda Pharmaceutical Company Limited | 2-isoindol-1,3,4-oxadiazole derivatives useful as HDAC6 inhibitors |
-
2020
- 2020-09-24 AU AU2020353984A patent/AU2020353984B2/en active Active
- 2020-09-24 PE PE2022000460A patent/PE20220711A1/es unknown
- 2020-09-24 MX MX2022003490A patent/MX2022003490A/es unknown
- 2020-09-24 AR ARP200102652A patent/AR120040A1/es unknown
- 2020-09-24 EP EP20800345.9A patent/EP4034536A1/en active Pending
- 2020-09-24 CA CA3156060A patent/CA3156060A1/en active Pending
- 2020-09-24 JP JP2022545275A patent/JP7602546B2/ja active Active
- 2020-09-24 BR BR112022005595A patent/BR112022005595A2/pt unknown
- 2020-09-24 US US17/030,504 patent/US11453661B2/en active Active
- 2020-09-24 KR KR1020227012924A patent/KR20220070465A/ko active Pending
- 2020-09-24 CN CN202080068097.3A patent/CN114846012B/zh active Active
- 2020-09-24 WO PCT/JP2020/037386 patent/WO2021060567A1/en not_active Ceased
- 2020-09-24 TW TW109133124A patent/TWI882012B/zh active
- 2020-09-24 IL IL291413A patent/IL291413B2/en unknown
- 2020-09-24 PH PH1/2022/550748A patent/PH12022550748A1/en unknown
-
2022
- 2022-03-25 CL CL2022000763A patent/CL2022000763A1/es unknown
- 2022-04-04 EC ECSENADI202226524A patent/ECSP22026524A/es unknown
- 2022-04-22 CO CONC2022/0005059A patent/CO2022005059A2/es unknown
- 2022-04-26 ZA ZA2022/04666A patent/ZA202204666B/en unknown
- 2022-09-26 US US17/952,546 patent/US11958845B2/en active Active
-
2024
- 2024-04-15 US US18/635,839 patent/US12384770B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW202126643A (zh) | 2021-07-16 |
| US12384770B2 (en) | 2025-08-12 |
| AU2020353984A1 (en) | 2022-04-21 |
| CO2022005059A2 (es) | 2022-07-08 |
| EP4034536A1 (en) | 2022-08-03 |
| AU2020353984A2 (en) | 2022-08-04 |
| WO2021060567A1 (en) | 2021-04-01 |
| CN114846012A (zh) | 2022-08-02 |
| JP7602546B2 (ja) | 2024-12-18 |
| AU2020353984B2 (en) | 2025-09-25 |
| TWI882012B (zh) | 2025-05-01 |
| US20230183227A1 (en) | 2023-06-15 |
| JP2022552444A (ja) | 2022-12-15 |
| MX2022003490A (es) | 2022-04-25 |
| IL291413B1 (en) | 2024-11-01 |
| KR20220070465A (ko) | 2022-05-31 |
| PE20220711A1 (es) | 2022-05-04 |
| US20210094944A1 (en) | 2021-04-01 |
| CA3156060A1 (en) | 2021-04-01 |
| US20240343721A1 (en) | 2024-10-17 |
| CL2022000763A1 (es) | 2023-01-20 |
| US11958845B2 (en) | 2024-04-16 |
| ZA202204666B (en) | 2023-11-29 |
| PH12022550748A1 (en) | 2023-11-20 |
| CN114846012B (zh) | 2024-01-26 |
| IL291413A (en) | 2022-05-01 |
| BR112022005595A2 (pt) | 2022-07-19 |
| ECSP22026524A (es) | 2022-05-31 |
| US11453661B2 (en) | 2022-09-27 |
| IL291413B2 (en) | 2025-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
| CO2022005059A2 (es) | Derivados de 2-isoindol-1,3,4-oxadiazol útiles como inhibidores de la histona desacetilasa 6 (hdac6) | |
| AR116604A1 (es) | Inhibidores de kras g12c | |
| CY1122821T1 (el) | Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2 | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| AR122783A2 (es) | Inhibidores de kras g12c y métodos para su uso | |
| BR112018067775A2 (pt) | inibidores de mcl-1 indol substituído | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR100691A1 (es) | Esteroides neuroactivos, composiciones, y usos de los mismos | |
| AR101177A1 (es) | Inhibidores de la syk | |
| EA201991693A1 (ru) | Производное пиридина в качестве ингибитора ask1 и способ его получения и применения | |
| BR112019000247A2 (pt) | derivados de 1,3-di-hidróxi-fenila úteis como imunomoduladores | |
| AR110038A1 (es) | Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos | |
| NI201500031A (es) | Métodos para tratar la enfermedad de alzheimer y composiciones farmacéuticas de los mismos. | |
| EA201790337A1 (ru) | Кристаллические формы ингибиторов глутаминазы | |
| EA201690204A1 (ru) | Соединения n,6-бис(арил или гетероарил)-1,3,5-триазин-2,4-диамина в качестве ингибиторов мутантов idh2 для лечения ракового заболевания | |
| MX2020003593A (es) | Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos. | |
| AR096620A1 (es) | Derivado de aminotriazina y composición farmacéutica que lo comprende | |
| MX2017014645A (es) | Profarmacos de alvocidib que tienen una biodisponibilidad aumentada. | |
| BR112015023009A2 (pt) | Moduladores de ship1 e métodos relacionados ao mesmo | |
| AR094812A1 (es) | Derivado de piridina monocíclico como inhibidor del fgfr | |
| EA201790758A1 (ru) | Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге | |
| EA201790328A1 (ru) | Диоксолановые аналоги уридина для лечения рака | |
| BR112018017303A2 (pt) | composto tipo piridazinona ou seu sal, e herbicida compreendendo o mesmo | |
| CL2019001041A1 (es) | Compuestos terapéuticos y métodos para utilizarlos. |